Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.

Autor: Sato, Akinori, Asano, Takako, Ito, Keiichi, Sumitomo, Makoto, Asano, Tomohiko
Předmět:
Zdroj: BJU International; Apr2012, Vol. 109 Issue 8, p1258-1268, 11p, 1 Chart, 6 Graphs
Abstrakt: What's known on the subject? and What does the study add? The treatment modality for advanced renal cancer is limited and new treatment approaches are urgently needed. Beneficial effects of bortezomib combined with SAHA have recently been reported. However, there are no previous reports of this combination being tested against renal cancer and its further mechanisms of action should be clarified. This study examined the combined effects of these two clinically feasible drugs and showed that the combination inhibits renal cancer cell proliferation by enhancing both protein ubiquitination and histone acetylation synergistically. OBJECTIVE [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index